ADJUVANT TREATMENT WITH BIPHOSPONATES IN COMPLEX THERAPY OF PAPILLARY THYROID CANCER BONE METASTASES

A. D. Kaprin; A. P. Polyakov; P. O. Rumiantsev; K. S. Nizegorodova; M. V. Degtiarev; P. A. Nikiforovich; M. V. Ratushnyy; O. V. Matorin; M. M. Filushin; I. V. Rebrikova; A. L. Sugaipov; A. V. Mordovskiy

doi:10.17709/2409-2231-2017-4-3-9

ADJUVANT TREATMENT WITH BIPHOSPONATES IN COMPLEX THERAPY OF PAPILLARY THYROID CANCER BONE METASTASES

A. D. Kaprin, A. P. Polyakov, P. O. Rumiantsev, K. S. Nizegorodova, M. V. Degtiarev, P. A. Nikiforovich, M. V. Ratushnyy, O. V. Matorin, M. M. Filushin, I. V. Rebrikova, A. L. Sugaipov, A. V. Mordovskiy

https://doi.org/10.17709/2409-2231-2017-4-3-9

Full Text:

PDF (Rus) |

Generate QR code

Abstract

Distant metastasis of thyroid cancer are founded in 10% of all metastases. Bone metastases are founded in 23% of distant metastasis. Complications associated with metastatic skeletal involvement often lead to a deterioration in the overall condition and a decrease in the quality of life of patients. Surgical treatment, chemotherapy are less effective, provide a higher injury rate and toxicity. This is a reason of increasing of cost of treatment. Bisphosphonates are a class of drugs that prevent the loss of bone mass, which can prolong the time to releasing bone complications: bone fracture, spine column fracture with spinal medulla compression, which decrease the QoL. Surgical treatment and chemotherapy have worse outcomes, higher injury rate, toxicity and increase cost of treatment. Bisphosphonates decrease the level of pain syndrome. Bisphosphonates are used in treatment of oncological patients since 1990. First medication was Fosamax (Aledronat). Later more medications with better efficacy and more useful were synthesised. The last one was Zoledronic acid. Rezorba (zoledronic acid) was synthesised in 2006 in Russia. Rezorba has a same efficacy with other bisphosphonates, it was shown in clinical studies with groups of breast cancer and prostatic cancer. Clinical case of 67 y.o. male patient with diagnosis: Thyroid cancer IV c st pT1bN1bM1, right neck, paratraсheal, bone and lung metastasis. Complex treatment (surgery + radioiodine therapy + 5 courses of Rezorba) was presented. After 3 courses the level of pain was decreased from 3 to 1,5. After 5 courses the ECOQ score was decreased from 2 to 1 point. Inclusion of Resorba in complex treatment of patients with bone metastasis after thyroid cancer at all stages of treatment decreases the score of pain syndrome and bone tissue reparation.

Keywords

pain syndrome, zoledronic acid, papillary thyroid cancer, bone resorption, bone metastases, quality of life

About the Authors

A. D. Kaprin

P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation
Russian Federation

academician of RAS, PhD, MD, Prof.;

Corr. member of the Russian Academy of Education;

Honored Physician of the Russian Federation;

General Director of National Medical Radiology Research Centre, 3, 2nd Botkinskiy proezd, Moscow, 125284;

Head of Department of Urology with Course of Urological Oncology, Faculty for Postgraduate Training, Peoples’ Friendship University of Russia

A. P. Polyakov

P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation
Russian Federation
PhD, Head of Department of Microsurgery

P. O. Rumiantsev

Endocrinology Research Center of the Ministry of Health of the Russian Federation
Russian Federation

MD, Head of the Radionuclide Diagnostics and Therapy Department,

11 ul. Dmitriya Ulianova, Moscow, 117036

K. S. Nizegorodova

Endocrinology Research Center of the Ministry of Health of the Russian Federation
Russian Federation
esearcher, Department of Radionuclide Diagnosis and Therapy

M. V. Degtiarev

Endocrinology Research Center of the Ministry of Health of the Russian Federation
Russian Federation
Head of the Department of Radionuclide Diagnosis and Therapy

P. A. Nikiforovich

P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian Federation
Russian Federation

Junior Researcher of Department of Microsurgery,

3, 2nd Botkinskiy proezd, Moscow, 125284

M. V. Ratushnyy

O. V. Matorin

M. M. Filushin

I. V. Rebrikova

A. L. Sugaipov

A. V. Mordovskiy

References

1. DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and coursof papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990 Aug; 71 (2): 414–24. DOI: 10.1210/jcem‑71–2-414

2. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical andmedical therapy on papillary and follicular thyroid cancer. Am J Med. 1994 Nov; 97 (5): 418–28. DOI: 10.1016/0002–9343 (94)90321–2

3. Schlumberger MJ. Papillary and follicular thyroid carcinoma. Baillieres Best Pract Res Clin Endocrinol Metab. 2000 Dec; 14 (4): 601–13. DOI: 10.1053/beem.2000.0105

4. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001 Apr; 86 (4): 1447–63. DOI: 10.1210/jcem.86.4.7407

5. Guise TA, Mundy GR. Cancer and bone. Endocr Rev. 1998 Feb; 19 (1): 18–54. DOI: 10.1210/edrv.19.1.0323

6. Kitamura Y, Shimizu K, Nagahama M, Sugino K, Ozaki O, Mimura T, et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal case. J Clin Endocrinol Metab. 1999 Nov; 84 (11): 4043–9. DOI: 10.1210/jcem.84.11.6115

7. Kuliev IE, Bessonova NS. Effektivnaya farmakoterapiya [Effective pharmacotherapy]. Мoscow, 2012. (In Russian).

8. Kaprin AD, Sivkov AV, Oshepkov BN, Gafanov RA, Keshishev NG. Rezorba in treatment of metastatic prostate cancer bone lesions. Experimental and Clinical Urology. 2010; 2: 34–36. (In Russian).

9. Harvey HA, Cream Lv. Biology of bone metastases: causes and conseguences. Clin Breast Cancer. 2007 Jul; 7 Suppl 1: S7‑S13.

10. Russell RG, Rogers MJ, Frith JC, Luckman SP, Coxon FP, Benford HL, et al. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res. 1999 Oct; 14 Suppl 2: 53–65.

11. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonatesinduce apoptosisin human breast cancer cell lines. Br J Cancer. 2000 Apr; 82 (8): 1459–68. DOI: 10.1054/bjoc.1999.1131

Review

For citations:

Kaprin A.D., Polyakov A.P., Rumiantsev P.O., Nizegorodova K.S., Degtiarev M.V., Nikiforovich P.A., Ratushnyy M.V., Matorin O.V., Filushin M.M., Rebrikova I.V., Sugaipov A.L., Mordovskiy A.V. ADJUVANT TREATMENT WITH BIPHOSPONATES IN COMPLEX THERAPY OF PAPILLARY THYROID CANCER BONE METASTASES. Research and Practical Medicine Journal. 2017;4(3):93-99. (In Russ.) https://doi.org/10.17709/2409-2231-2017-4-3-9

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2410-1893 (Online)

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Research and Practical Medicine Journal

ADJUVANT TREATMENT WITH BIPHOSPONATES IN COMPLEX THERAPY OF PAPILLARY THYROID CANCER BONE METASTASES

Full Text:

Abstract

Keywords

About the Authors

References

Review

For citations:

Cookies policy